the aadi bioscience ( aADI ) program is a new and exciting technology that is a powerful tool for treating patients with malignant uterine pecoma. we have been able to deliver the first drug for the treatment of malignant pecoma in 10 months and we have received a permanent j code for fiscalaro. we have achieved sales of $15.2 million in 2022 outperforming estimates for the year in just 10 months on the market. we are excited about the potential benefits of fiscalaro for patients beyond pecoma. we are excited about the potential benefits for patients beyond pecoma. we will now turn it back to our chief medical officer, a chief medical officer and a new trial in patients with a mutation in the mri pathway.